There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Addus Homecare (ADUS – Research Report), Telix Pharmaceuticals Ltd. (TLPPF – Research Report) and Intuitive Surgical (ISRG – Research Report) with bullish sentiments.
Addus Homecare (ADUS)
In a report released today, Joanna Gajuk from Bank of America Securities maintained a Buy rating on Addus Homecare, with a price target of $115.00. The company’s shares closed last Monday at $93.49.
According to TipRanks.com, Gajuk is a 2-star analyst with an average return of
Currently, the analyst consensus on Addus Homecare is a Strong Buy with an average price target of $110.43.
See the top stocks recommended by analysts >>
Telix Pharmaceuticals Ltd. (TLPPF)
Wilsons analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals Ltd. on April 18 and set a price target of A$14.50. The company’s shares closed last Monday at $9.14, close to its 52-week high of $9.15.
According to TipRanks.com, Storey is a 3-star analyst with an average return of
Telix Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $10.13, representing a 10.7% upside. In a report issued on April 17, Jefferies also maintained a Buy rating on the stock with a A$15.30 price target.
Intuitive Surgical (ISRG)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Intuitive Surgical, with a price target of $416.00. The company’s shares closed last Monday at $368.93.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $423.59, implying a 14.6% upside from current levels. In a report issued on April 8, Stifel Nicolaus also maintained a Buy rating on the stock with a $430.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ADUS:
- Addus HomeCare price target raised to $115 from $110 at Stephens
- Addus HomeCare price target raised to $115 from $108 at BofA
- Addus HomeCare initiated with an Equal Weight at Barclays
- Addus Homecare Unveils Year-End Financial Performance
- Addus HomeCare CEO ‘optimistic’ about acquisition opportunities in 2024
